Ostene is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or increase the risk of surgical infections, including MRSA.
The novel biomaterial is used in cardiac, orthopedic, and neurosurgery and has additional applications as a safe, soluble delivery vehicle for a variety of therapeutic agents, from antibiotics to bone growth factors. The use of Ostene in cardiac surgery may help reduce the risk of sternal wound infection and prevent the post-operative separation of the sternum, much feared complications.
Dr Tadeusz Wellisz, Ceremed’s president and CEO, said: “The agreement with Nycomed provides us with a partner who will help us pursue a full cardiac, orthopedic, and neurosurgical development program for Ostene in Europe. We appreciate Nycomed’s expertise in this territory, and we look forward to working with Nycomed’s tissue management team on bringing Ostene to patients throughout Europe. Ostene’s unique antibacterial properties are particularly significant now that we are battling the threat of hospital-acquired infections, especially MRSA.”